Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2021-11-03 Director's Dealing
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2021-11-03 English
FORM 4
Director's Dealing
2021-11-03 English
FORM 4
Director's Dealing
2021-11-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions Item 2.02, which relates to "Results of Operations and Financial Condition," and includes a press release about financial results for the three and nine months ended September 30, 2021. The document states that the press release is furnished as an exhibit and is not filed as part of a formal quarterly or annual report. The length of the document is 3410 characters, which is relatively short and consistent with a current report or announcement rather than a full interim or annual report. The document does not contain detailed financial statements or substantive financial data itself but references a press release. According to the classification rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but not the full financial report itself, and it is not a certification or a report publication announcement. Therefore, the appropriate classification is RNS with high confidence.
2021-10-28 English
10-Q
Interim / Quarterly Report Q3 2021
2021-10-28 English
FORM 4
Director's Dealing
2021-10-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.